Hong Kong’s Department of Health is investigating alleged claims that the Hong Kong Asia-Pacific Medical Centre offered a “WT1” vaccine that could prevent multiple cancers, after conducting surprise inspections at seven premises. The department said the product is not a registered pharmaceutical product in Hong Kong and that claims promoting it for cancer prevention are misleading.
The vaccine was reportedly promoted on social media or through other publicity as protecting against multiple cancers. Reports put the alleged price at HK$120,000, although it has not been established whether the fee was actually collected.
The Department of Health said it received a complaint in July 2026 about the centre’s alleged promotion of WT1. The surprise inspections of the centre and six other premises took place on 31 August, according to the reports.
The case has been referred to the Medical Council of Hong Kong and Customs for follow-up, while relevant mainland enforcement authorities have also been notified, the department said.
The department warned that illegally supplying an unregistered medicine may constitute a criminal offence. One report also said the authorities described the claims as potentially involving fraud. These are legal or enforcement assessments, not confirmed convictions.
The department was also reported to have found no registration records for WT1 with mainland or overseas regulators, although the reports provided no independent verification of that position. Authorities have not disclosed the full list of inspected premises, the product’s contents or supply arrangements, whether anyone received it, or whether further action has been taken by the bodies involved.